Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET)
CUSIP: 007002108
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.0001
- Shares outstanding
- 9,599,852
- Total 13F shares
- 51,335,037
- Share change
- -268,034
- Total reported value
- $41,591,047
- Price per share
- $0.81
- Number of holders
- 53
- Value change
- -$36,555
- Number of buys
- 24
- Number of sells
- 17
Quarterly Holders Quick Answers
What is CUSIP 007002108?
CUSIP 007002108 identifies ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 007002108:
Top shareholders of ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
119%
|
11,447,140
|
$6,982,755 | — | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
9.9%
|
8,223,612
|
$6,208,827 | $0 | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
79%
|
7,541,000
|
$4,600,010 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
39%
|
3,752,098
|
$2,288,780 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
34%
|
3,272,522
|
$1,996,238 | — | 30 Jun 2025 | |
| Carlyle Group Inc. |
13F
|
Company |
31%
|
2,948,718
|
$1,801,077 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
22%
|
2,074,604
|
$1,263,000 | — | 30 Jun 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
20%
|
1,880,095
|
$1,146,854 | — | 30 Jun 2025 | |
| Carl L. Gordon |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
684,857
mixed-class rows
|
$941,594 | — | 21 Aug 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
12%
|
1,153,816
|
$703,828 | — | 30 Jun 2025 | |
| REGENERON PHARMACEUTICALS, INC. |
13F
|
Company |
10%
|
968,183
|
$590,592 | — | 30 Jun 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
9.4%
|
901,600
|
$549,976 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
7.4%
|
706,334
|
$430,980 | — | 30 Jun 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
6.8%
|
655,665
|
$399,956 | — | 30 Jun 2025 | |
| RBF Capital, LLC |
13F
|
Company |
6.4%
|
617,319
|
$376,565 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.2%
|
599,487
|
$365,688 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
6.2%
|
592,327
|
$361,319 | — | 30 Jun 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
5.9%
|
566,039
|
$345,284 | — | 30 Jun 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
5.6%
|
540,000
|
$329,400 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
5.3%
|
512,807
|
$312,812 | — | 30 Jun 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
4.8%
|
460,406
|
$280,848 | — | 30 Jun 2025 | |
| Francesco Galimi |
3/4/5
|
SVP & Chief Medical Officer |
—
mixed-class rows
|
476,878
mixed-class rows
|
$244,322 | — | 05 Jun 2024 | |
| JOHNSON & JOHNSON |
13F
|
Company |
3.8%
|
364,472
|
$228,014 | — | 30 Jun 2025 | |
| Aya Jakobovits |
3/4/5
|
Director |
—
mixed-class rows
|
176,276
mixed-class rows
|
$214,323 | — | 21 Aug 2024 | |
| WEALTHEDGE INVESTMENT ADVISORS, LLC |
13F
|
Company |
3.3%
|
313,108
|
$190,996 | — | 30 Jun 2025 | |
| LUMINUS MANAGEMENT LLC |
13F
|
Company |
3%
|
289,935
|
$176,860 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.6%
|
246,921
|
$150,622 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
2.5%
|
244,778
|
$149,315 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
1.6%
|
150,000
|
$91,500 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1.5%
|
140,373
|
$85,628 | — | 30 Jun 2025 | |
| Lloyd Klickstein |
3/4/5
|
Director |
—
mixed-class rows
|
134,966
mixed-class rows
|
$66,225 | — | 11 Jun 2025 | |
| Vontobel Holding Ltd. |
13F
|
Company |
0.83%
|
80,000
|
$48,800 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.75%
|
72,226
|
$44,059 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.6%
|
57,268
|
$34,934 | — | 30 Jun 2025 | |
| Abacus Planning Group, Inc. |
13F
|
Company |
0.38%
|
36,764
|
$22,426 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.31%
|
30,000
|
$18,300 | — | 30 Jun 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.3%
|
29,059
|
$17,726 | — | 30 Jun 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.25%
|
23,580
|
$14,384 | — | 30 Jun 2025 | |
| Steve Dubin |
3/4/5
|
Director |
—
mixed-class rows
|
49,100
mixed-class rows
|
$13,847 | — | 11 Jun 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.23%
|
22,199
|
$13,541 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.21%
|
20,635
|
$12,587 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.21%
|
19,957
|
$12,174 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.19%
|
18,508
|
$11,290 | — | 30 Jun 2025 | |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. |
13F
|
Company |
0.19%
|
17,846
|
$10,886 | — | 30 Jun 2025 | |
| Andrew Sinclair |
3/4/5
|
Director |
—
mixed-class rows
|
44,100
mixed-class rows
|
$10,797 | — | 11 Jun 2025 | |
| Jeffrey Chodakewitz |
3/4/5
|
Director |
—
mixed-class rows
|
44,100
mixed-class rows
|
$10,797 | — | 11 Jun 2025 | |
| Michael Kauffman |
3/4/5
|
Director |
—
mixed-class rows
|
32,300
mixed-class rows
|
$8,437 | — | 21 Aug 2024 | |
| Katie Peng |
3/4/5
|
Director |
—
mixed-class rows
|
38,200
mixed-class rows
|
$7,198 | — | 11 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.04%
|
3,752
|
$2,289 | — | 30 Jun 2025 | |
| HOLLENCREST CAPITAL MANAGEMENT |
13F
|
Company |
0.02%
|
2,000
|
$1,220 | — | 30 Jun 2025 |
Institutional Holders of Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) as of Q3 2025
As of 30 Sep 2025,
Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET) was held by
53 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,335,037 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, TANG CAPITAL MANAGEMENT LLC, RA CAPITAL MANAGEMENT, L.P., GOLDMAN SACHS GROUP INC, VANGUARD GROUP INC, Carlyle Group Inc., ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, REGENERON PHARMACEUTICALS, INC., and BRIDGEWAY CAPITAL MANAGEMENT, LLC.
This page lists
54
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
47
Q3 2025 holders
53
Holder diff
6
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.